Date Title Description PDF
25 Mar 2025 On business and financial situation The Company releases the presentation related to its strategy update because of its 2025 Capital Markets Day Download
25 Feb 2025 On P&L The Company releases the press release related to the full year 2024 financial results Download
25 Feb 2025 On P&L The Company releases the full year 2024 financial results presentation Download
25 Feb 2025 About Corporate Governance The Company informs about the agreements adopted by the Board of Directors Download
07 Feb 2025 On P&L The Company informs on some of the results expected by the market consensus Download

Pages

Date Title Description PDF
15 Dec 2023 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 11 December and 14 December 2023 Download
11 Dec 2023 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 1 December and 8 December 2023 Download
01 Dec 2023 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 24 November and 30 November 2023 Download
24 Nov 2023 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 17 November and 23 November 2023 Download
17 Nov 2023 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 10 November and 16 November 2023 Download

Pages

Date Title Description PDF
08 Jan 2018 Contratos de liquidez y contrapartida Liquidity contract: transactions conducted in the fourth quarter of 2017 Download
21 Dec 2017 Préstamos, créditos y avales ROVI and the EIB agree to sign a loan to boost research into drug administration and prolonged-release technologies Download
08 Nov 2017 Información sobre Resultados ROVI releases the press release related to the nine-month period ended 30 September 2017 results Download
08 Nov 2017 Información sobre Resultados ROVI releases the presentation related to the nine-month period ended 30 September 2017 results. Download
24 Oct 2017 Otros sobre negocio y situación financiera The Company releases the presentation related to the update of its Phase III-Prima 3 Risperidone ISM® project. Download

Pages